You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment

https://doi.org/10.1136/eb-2012-100789

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests AN has received lecture fees from Boehringer Ingelheim, served on an advisory board for Boehringer Ingelheim and received travel fees from Boehringer Ingelheim, Daiichi Sankyo and Pfizer.